122 related articles for article (PubMed ID: 33491761)
1. Role of primary cilium in pancreatic ductal adenocarcinoma (Review).
Sabanovic B; Giulietti M; Piva F
Int J Oncol; 2020 Nov; 57(5):1095-1102. PubMed ID: 33491761
[TBL] [Abstract][Full Text] [Related]
2. HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.
Kobayashi T; Nakazono K; Tokuda M; Mashima Y; Dynlacht BD; Itoh H
EMBO Rep; 2017 Feb; 18(2):334-343. PubMed ID: 28028031
[TBL] [Abstract][Full Text] [Related]
3. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
Bangs FK; Miller P; O'Neill E
Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
5. ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
[TBL] [Abstract][Full Text] [Related]
6. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
10. Loss of a primary cilium in PDAC.
Kobayashi T; Itoh H
Cell Cycle; 2017 May; 16(9):817-818. PubMed ID: 28319439
[No Abstract] [Full Text] [Related]
11. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
12. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
13. Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas.
Giry-Laterriere M; Pinho AV; Eling N; Chantrill L; Rooman I
Curr Cancer Drug Targets; 2015; 15(6):463-8. PubMed ID: 26282546
[TBL] [Abstract][Full Text] [Related]
14. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.
Morris JP; Wang SC; Hebrok M
Nat Rev Cancer; 2010 Oct; 10(10):683-95. PubMed ID: 20814421
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
16. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
17. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
20. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
